

CD40 antibody [FGK4.5/ FGK45]

Cat. No. GTX01483

Host	Rat
Clonality	Monoclonal
Isotype	IgG2a
Applications	FCM
Reactivity	Mouse

References (4)

Package

100 µg

PRODUCT

Summary

The FGK45 antibody reacts with mouse CD40, a 40-50 kDa glycoprotein member of the tumor necrosis factor receptor (TNFR) family. CD40 is constitutively expressed by antigen presenting cells, including dendritic cells, B cells, and macrophages. The interaction of CD40 and its ligand CD154, expressed on activated T cells, plays an essential role in mediating a broad range of immune and inflammatory responses including T cell dependent immunoglobulin class switching, germinal center formation, and the development of memory B cells. The FGK45 clone is reported to be functionally useful for both in vitro and in vivo activation of CD40 expressing antigen presenting cells. The FGK45 antibody reacts with mouse CD40, a 40-50 kDa glycoprotein member of the tumor necrosis factor receptor (TNFR) family.

Applications

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
FCM	Assay dependent
Inhibition assay	Assay dependent

Not tested in other applications.

Properties

Form	Liquid
Buffer	10mM NaH ₂ PO ₄ , 150mM NaCl
Preservative	0.09% Sodium azide
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4°C.
Concentration	0.5 mg/ml (Please refer to the vial label for the specific concentration.)
Purification	Purified by affinity chromatography From tissue culture supernatant
Conjugation	Unconjugated



For full product information, images and publications, please visit our [website](#).

For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Note

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.



For full product information, images and publications, please visit our [website](#).